Scarica l'app Stockscreener
3.30
1.54%
0.05
Dopo l'orario di chiusura:
3.26
-0.04
-1.21%
Precedente Chiudi:
$3.25
Aprire:
$3.26
Volume 24 ore:
899.74K
Relative Volume:
0.44
Capitalizzazione di mercato:
$317.76M
Reddito:
-
Utile/perdita netta:
$-84.23M
Rapporto P/E:
-3.5726
EPS:
-0.9237
Flusso di cassa netto:
$-77.15M
1 W Prestazione:
+6.45%
1M Prestazione:
+6.45%
6M Prestazione:
-65.48%
1 anno Prestazione:
-15.17%
Intervallo 1D:
$3.1833
$3.34
Intervallo di 1 settimana:
$3.075
$3.43
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.30 | 312.95M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Balyasny holds 5,048,421 shares of Rezolute (NASDAQ: RZLT), ~5.28% stake - Stock Titan
RZLT Maintains by Maxim Group -- Price Target Raised to $10.00 - GuruFocus
FDA review puts Rezolute's genetic disorder drug path in question - MSN
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
High Growth Tech Stocks in US for May 2026 - simplywall.st
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target - Investing.com UK
H.C. Wainwright reiterates Buy on Rezolute stock, $5 target By Investing.com - Investing.com Nigeria
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - The Manila Times
TradingKey - TradingKey
Rezolute (RZLT) Q3 FY2026 Earnings: EPS Not Disclosed, Revenue N - GuruFocus
RZLT Reports Significant Decrease in Cash Reserves - GuruFocus
Rezolute, Inc. 3Q 2026: Net loss $16.2M, EPS $(0.16) — 10-Q Summary - TradingView
Rezolute (NASDAQ: RZLT) details sunRIZE miss and tumor HI Phase 3 - Stock Titan
Rezolute 3Q Loss/Shr 16c >RZLT - Moomoo
Rezolute (NASDAQ: RZLT) Q3 2026 loss narrows with HI efficacy data - Stock Titan
MSN Money - MSN
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT) - Stock Titan
Number of shareholders of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Rezolute Inc. to Present Clinical Development Programs at Investor Conferences - geneonline.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
About Us | Oil & Gas JournalRezolute to Participate in Upcoming Investor Conferences - FinancialContent
Rezolute Announces Positive Phase 3 sunRIZE Results for Ersodetug in Congenital Hyperinsulinism, Shows Significant Glycemic Improvements and FDA Progress 1234 - Minichart
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA - TipRanks
Phase 3 sunRIZE miss but strong CGM gains for Rezolute (NASDAQ: RZLT) - Stock Titan
Rezolute Buy Rating Reiterated as CGM Data Offset Phase 3 Miss; $5 Price Target Maintained - TipRanks
H.C. Wainwright reiterates Rezolute stock rating on CGM data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Rezolute stock rating on CGM data - Investing.com
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com - Investing.com Australia
Rezolute (RZLT) Presents Positive Findings from Phase 3 sunRIZE Study - GuruFocus
Rezolute presents expanded Phase 3 data for hyperinsulinism drug - Investing.com
Rezolute, Inc. Reports Positive Continuous Glucose Monitoring Outcomes for Ersodetug in Phase 3 sunRIZE Study of Congenital Hyperinsulinism - Quiver Quantitative
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in ... - Caledonian Record
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting - The Killeen Daily Herald
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):